AstraZeneca/Daiichi Sankyo ADC Pact Continues Clinical Success In Breast Cancer
Early TNBC Efficacy Signs From Datopotamab Deruxtecan
While much earlier in its development, the drug may be able to rival Gilead’s Trodelvy, which also targets TROP2 and showed similar response rates.
